“Per a recently published analysis by the Montreal Heart Institute, the candidate could potentially reduce cardiovascular morbidity and mortality by as much as 39% in patients with a specific genetic profile.”
“Last quarter, the company had delivered a positive earnings surprise of 12.8%. Notably, Edwards’ earnings have outpaced the Zacks Consensus Estimate in all of the past four quarters, with an average beat of 12.5%. Let’s see how things are shaping up prior to this announcement. ”
“Therapeutics Inc.’s new drug application (NDA) for its enclomiphene citrate product candidate, which was previously known as Androxal, has been accepted for review by the FDA. The company is looking to get the candidate approved for the treatment of secondary hypogonadism in overweight men wish
1
Zacks Investment Research: Stock Research, Analysis, & Recommendations
Zacks Investment Research: Stock Research, Analysis, & Recommendations
Zacks Investment Research: Stock Research, Analysis, & Recommendations
Zacks Investment Research: Stock Research, Analysis, & Recommendations
Zacks Investment Research: Stock Research, Analysis, & Recommendations
